spironolactone has been researched along with Arteriosclerosis in 13 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have demonstrated previously that infusion of angiotensin II (AngII) into hyperlipidemic mice augments atherosclerosis and results in the formation of abdominal aortic aneurysms (AAA)." | 7.73 | Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. ( Cassis, LA; Daugherty, A; Helton, MJ; Howatt, DA; King, VL, 2005) |
| "We have demonstrated previously that infusion of angiotensin II (AngII) into hyperlipidemic mice augments atherosclerosis and results in the formation of abdominal aortic aneurysms (AAA)." | 3.73 | Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. ( Cassis, LA; Daugherty, A; Helton, MJ; Howatt, DA; King, VL, 2005) |
| "Aldosterone, which has an important role in the pathology of heart failure, has recently been implicated as a mediator of AT-II biologic activities." | 1.32 | Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. ( Aviram, M; Coleman, R; Hamoud, S; Hayek, T; Kaplan, M; Keidar, S; Pavlotzky, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeMarco, VG | 1 |
| Habibi, J | 1 |
| Jia, G | 1 |
| Aroor, AR | 1 |
| Ramirez-Perez, FI | 1 |
| Martinez-Lemus, LA | 1 |
| Bender, SB | 1 |
| Garro, M | 1 |
| Hayden, MR | 1 |
| Sun, Z | 1 |
| Meininger, GA | 1 |
| Manrique, C | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Korkmaz, ME | 1 |
| Atar, I | 1 |
| Tayfun, E | 1 |
| Yildirir, A | 1 |
| Ulucam, M | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 1 |
| Turan, M | 1 |
| Keidar, S | 2 |
| Hayek, T | 2 |
| Kaplan, M | 2 |
| Pavlotzky, E | 2 |
| Hamoud, S | 2 |
| Coleman, R | 2 |
| Aviram, M | 2 |
| SETTEL, E | 1 |
| Cassis, LA | 1 |
| Helton, MJ | 1 |
| Howatt, DA | 1 |
| King, VL | 1 |
| Daugherty, A | 1 |
| Karagiannis, A | 1 |
| Tziomalos, K | 1 |
| Dona, K | 1 |
| Pyrpasopoulou, A | 1 |
| Kartali, N | 1 |
| Athyros, V | 1 |
| Zamboulis, C | 1 |
| Rajagopalan, S | 1 |
| Duquaine, D | 1 |
| King, S | 1 |
| Pitt, B | 1 |
| Patel, P | 1 |
| Voudoukis, IJ | 1 |
| Sycheva, IM | 3 |
| Vinogradov, AV | 3 |
| Speranskaia, NV | 2 |
| Kramer, AA | 2 |
| Ignatova, TA | 2 |
| Bezborod'ko, BN | 1 |
| Shekhunova, MI | 1 |
| Selivonenko, VG | 1 |
| Krater, AA | 1 |
| Matveev, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for spironolactone and Arteriosclerosis
| Article | Year |
|---|---|
Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.
Topics: Animals; Aorta; Arteriosclerosis; Diet, Western; Dose-Response Relationship, Drug; Endothelial Cells | 2015 |
Effects of a beta-blocker and spironolactone on plasma homocysteine levels.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arteriosclerosis; Homocysteine; Humans; Metoprolol; Middle | 2003 |
Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Apolipoproteins E; Arteriosclerosis; Aryldialkylphosphatase; Blood Pressure; E | 2003 |
FURTHER EXPERIENCE WITH SPIRONOLACTONE-HYDRO-CHLOROTHIAZIDE (ALDACTAZIDE-A) IN THE LONG-TERM TREATMENT OF REFRACTORY CARDIAC EDEMA.
Topics: Arteriosclerosis; Chlorothiazide; Coronary Disease; Drug Combinations; Drug Therapy; Edema; Edema, C | 1965 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.
Topics: Aldosterone; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Arteriosclerosi | 2005 |
Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient.
Topics: Adrenal Glands; Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2005 |
Mineralocorticoid receptor antagonism in experimental atherosclerosis.
Topics: Animals; Aorta; Arteriosclerosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Eplerenon | 2002 |
Prognostic and therapeutic considerations in pure hypertension vs hypertension and superimposed arteriosclerosis.
Topics: Arteriosclerosis; Blood Pressure; Cold Temperature; Digitalis; Female; Follow-Up Studies; Humans; Hy | 1975 |
[Alterations in water-salt metabolism under the influence of diuretics in cardiac insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Ethacrynic Acid; Female; Heart Failure; Humans; Mal | 1973 |
[Use of aldactone and veroshpiron in complex therapy of patients with circulation disorders].
Topics: Adolescent; Adult; Aged; Arteriosclerosis; Calcium; Female; Heart Diseases; Humans; Hypertension; Ma | 1973 |
[Changes in water-salt metabolism in cardiac insufficiency under the influence of diuretic preparations].
Topics: Adult; Aged; Arteriosclerosis; Body Fluids; Chronic Disease; Coronary Disease; Diet Therapy; Ethacry | 1973 |
[Concentration of metabolizable sodium in patients with circulatory insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Female; Heart Failure; Humans; Male; Middle Aged; Rheumatic Heart Dis | 1971 |